Merger Model: Accretion/Dilution and Pro Forma EPS Worked Step by Step

Step 1: combine the income statements. Add the acquirer's and target's net income, then apply synergies (typically modeled as a single line addition to combined EBIT, then tax-effected) and subtract any new amortization of intangibles created by the deal. Step 2: adjust for financing. New debt creates interest expense (tax-effected); new stock issuance increases share count; cash used reduces interest income (or increases interest expense if existing cash is replaced by new debt). Step 3: divide pro forma combined net income by pro forma diluted shares outstanding to get pro forma EPS. Compare to acquirer standalone EPS: HIGHER = ACCRETIVE, LOWER = DILUTIVE. Magnitude matters: a 5%+ accretive deal is usually celebrated; a 5%+ dilutive deal must be justified by long-term value creation (synergies that ramp, strategic positioning).

ALL CASH: acquirer uses cash on hand. Reduces interest income at the (low) cash yield. Most accretive financing typically because cash yields are far below earnings yields. Limit: how much cash the acquirer has plus how much debt it is willing to add. ALL DEBT: acquirer borrows to fund the purchase. Creates interest expense at the (higher) borrowing rate but no new shares. Accretion depends on whether the target's earnings yield exceeds the after-tax cost of debt. RULE OF THUMB: deal is accretive if (target earnings yield × (1 − tax rate)) > pre-tax cost of debt × (1 − tax rate). ALL STOCK: acquirer issues new shares. No interest expense impact but adds new shares to the denominator. RULE OF THUMB: deal is accretive if target P/E < acquirer P/E (acquirer is paying fewer of its expensive earnings per dollar of cheaper target earnings). Most deals mix all three. Modeling the mix lets you test where the breakeven sits.

REVENUE SYNERGIES — additional revenue from cross-selling, new market access, or product bundling — are the hardest to realize and most often missed. Sponsors should model them conservatively (50-70% haircut typical). COST SYNERGIES — eliminating duplicate functions (HR, finance, legal, IT), facility consolidation, procurement leverage, technology integration — are more reliably captured. Cost synergies are usually modeled as a one-time lump sum reaching steady state in 1-3 years with associated restructuring charges. Always show synergies in YEAR-BY-YEAR ramp rather than full from day one. Net income impact = synergy × (1 − tax rate). Restructuring costs in year 1 typically equal 1-2 years of cost synergies as a one-time investment to capture the recurring savings.

Acquirer: $200M net income, 100M shares, EPS $2.00, share price $40 (20x P/E), $500M cash, 25% tax rate, 5% pre-tax cost of debt. Target: $100M net income, $5B purchase price (50x P/E — a fast-growing target). Financing mix: 50% cash ($2.5B), 30% debt ($1.5B at 5% pre-tax, after-tax cost 3.75%), 20% stock ($1.0B / $40 = 25M new shares). SYNERGIES: $200M after-tax run-rate by year 3, 50% in year 1, 75% in year 2, 100% in year 3. NEW INTANGIBLE AMORTIZATION: $50M/year pre-tax = $37.5M after-tax (assuming all goodwill purchase price allocated). YEAR 1 PRO FORMA: NI = $200 + $100 + $100 synergies × (1 − 0.25) + $75 ramp = $200 + $100 + $75 − $37.5 amort − $1500M × 5% × 0.75 (after-tax interest) − $2500M × 1.5% × 0.75 (foregone cash interest) = $200 + $100 + $75 − $37.5 − $56.3 − $28.1 = $253.1M. NEW SHARES: 100 + 25 = 125M. PRO FORMA EPS = $253.1M / 125M = $2.02. Versus standalone $2.00 → 1% ACCRETIVE in year 1. Year 3 EPS likely meaningfully higher as synergies ramp.

The acquired target's assets are written up to fair value on the acquirer's balance sheet at the close. Excess of purchase price over the fair value of identifiable net assets is GOODWILL — not amortized but tested for impairment annually. IDENTIFIABLE INTANGIBLES (customer lists, technology, brand, trade names) are amortized over their useful lives (typically 5-15 years), creating new amortization expense that hits the income statement. Tax basis often does not change in a stock deal, so book-tax differences create DTLs. The amortization is non-cash but reduces reported EPS. SOME COMPANIES report "cash EPS" or "adjusted EPS" excluding M&A-related amortization to show underlying performance — controversial but common in industries with heavy M&A.

Investment bankers present accretion/dilution as a TWO-WAY SENSITIVITY TABLE. Rows: synergy assumption (50%, 75%, 100%, 125% of base). Columns: purchase price (or P/E multiple paid). Cell value: year 1 or year 3 EPS accretion percent. Reviewers and boards focus on: (a) is the deal accretive at any reasonable assumption, (b) how much synergy must be achieved to hit breakeven, (c) what does the upside look like in a favorable case. A deal that is dilutive at base-case synergies and only becomes accretive at heroic assumptions is a red flag. Bankers also run THREE-WAY SENSITIVITY across financing mix, showing the trade-off between cash (most accretive but constrained), debt (carries financial risk), and stock (signals over-valuation to the target).

Provide acquirer and target financials (net income, shares, share price, tax rate), the deal structure (purchase price, financing mix, synergy assumptions, intangible amortization), and FinanceIQ computes the pro forma EPS across years, applies the synergy ramp, and produces the accretion/dilution result with sensitivity tables across synergy and financing assumptions. This content is for educational purposes only and does not constitute investment advice.